Live Breaking News & Updates on Martin Lehr

Stay updated with breaking news from Martin lehr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Gina Mangiaracina , Jennifer Minai Azary , Martin Lehr , Context Therapeutics Inc , Exchange Commission , Drug Administration , Company Nasdaq , Therapeutics Reports First Quarter , Investigational New Drug , Recent Corporate , Annual Needham Virtual Healthcare , Private Securities Litigation Reform Act , Months Ended March , Relations Contact ,

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of ...

CTIM-76Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers ....

United States , Jennifer Minai Azary , Gina Mangiaracina , Martin Lehr , Context Therapeutics Inc , Company Nasdaq , Drug Administration , Exchange Commission , Investigational New Drug , Context Therapeutics , Private Securities Litigation Reform Act , Relations Contact ,

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 Context Therapeutics. ....

United States , Jennifer Minai Azary , Gina Mangiaracina , Martin Lehr , Context Therapeutics Inc , Exchange Commission , Drug Administration , Company Nasdaq , Investigational New Drug , Private Securities Litigation Reform Act , Relations Contact ,

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 Context Therapeutics Inc. , a biopharmaceutical company advancing medicines for solid. ....

United States , Martin Lehr , Jennifer Minai Azary , Gina Mangiaracina , Drug Administration , Context Therapeutics Inc , Company Nasdaq , Exchange Commission , Investigational New Drug , Private Securities Litigation Reform Act , Relations Contact ,

Context Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024

Context Therapeutics (NASDAQ:CNTX) has announced its third-quarter results, highlighting its progress in advancing its lead candidate, CTIM-76, a Claudin 6. ....

Martin Lehr , Drug Administration , Society For Immunotherapy Of Cancer , Context Therapeutics , Investigational New Drug , Annual Meeting ,